Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
BioSpace17h
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Business Wire18h
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
GlobalData on MSN17h
Regeneron’s macular oedema therapy shows promise in Phase III trial
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Bristol Myers announces results from Phase 2 TRANSCEND FL trial
Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...